Clinical trials: Hypohidrotic Ectodermal Dysplasia

X-linked Hypohidrotic Ectodermal Dysplasia

A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200

• Completed
• Age: 18 to 40 years
• Phase 1

Following discussions with the FDA, a Phase 1 safety study is being initiated in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)-affected adults to develop safety and exposure data for EDI200 in anticipation of dosing…

Trial name

NCT01564225

Testing

EDI200

Where

2 sites in United States

Volunteers

6 people

Sponsor

Edimer Pharmaceuticals